Maxim Group Believes VolitionRX (VNRX) Won’t Stop Here


In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on VolitionRX (VNRX), with a price target of $6. The company’s shares opened today at $3.40, close to its 52-week high of $3.45.

McCarthy commented:

“VolitionRx reported 4Q18 with a net loss of ($4.1M). The company ended the period with $13.4M in cash, which does not include an additional $6.7M in warrant exercises in 1Q19. The company has maintained a cash burn of ~ $3.9M, so we estimate VolitionRx has runway into 1H20.”

According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.9% and a 32.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.

VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $6.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.45 and a one-year low of $1.44. Currently, VolitionRX has an average volume of 106.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts